NCT02108964 - A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies | Biotech Hunter

Enrollment

225

Participants

Timeline

Start Date

June 6, 2014

Primary Completion Date

March 22, 2018

Study Completion Date

August 15, 2023

Conditions

Advanced Non-small Cell Lung Cancer

Interventions

DRUG

EGF816

EGF816 will be dosed once daily. On the first day of each treatment cycle, the patient receives an adequate drug supply for self-administration at home. The investigator will instruct the patient to take EGF816 exactly as prescribed.

Trial Locations (14)

10002

Novartis Investigative Site, Taipei

10017

Memorial Sloan Kettering Oncology Department, New York

13125

Novartis Investigative Site, Berlin

28041

Novartis Investigative Site, Madrid

50937

Novartis Investigative Site, Cologne

168583

Novartis Investigative Site, Singapore

02114

Massachusetts General Hospital Mass General, Boston

M5G 2M9

Novartis Investigative Site, Toronto

464 8681

Novartis Investigative Site, Nagoya

811-1395

Novartis Investigative Site, Fukuoka

NL-2722 EP

Novartis Investigative Site, Zoetermeer

03080

Novartis Investigative Site, Seoul

05505

Novartis Investigative Site, Seoul

08035

Novartis Investigative Site, Barcelona